Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Minton

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
Scandinavian Journal of Gastroenterology. Supplement|January 1, 1986
The response of a non-functional VIP- and somatostatin-containing tumour to tolbutamide in vitroE A Woltering, T M O'Dorisio, H S Mekhjian, et al.
Journal of Surgical Oncology|January 1, 1979
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230A Awrich, W S Fletcher, J H Klotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Cancer Treatment Reports|May 1, 1976
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)R D Carter, E T Krementz, G J Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Cancer|March 15, 1985
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer studyJ P Minton, J L Hoehn, D M Gerber, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
Scandinavian Journal of Gastroenterology. Supplement|January 1, 1986
The response of a non-functional VIP- and somatostatin-containing tumour to tolbutamide in vitroE A Woltering, T M O'Dorisio, H S Mekhjian, et al.
Journal of Surgical Oncology|January 1, 1979
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230A Awrich, W S Fletcher, J H Klotz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Cancer Treatment Reports|May 1, 1976
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)R D Carter, E T Krementz, G J Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Cancer|March 15, 1985
Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer studyJ P Minton, J L Hoehn, D M Gerber, et al.
Pageof 12